Memorial Sloan Kettering Cancer Center – Ghassan Abou-Alfa, MD

Ghassan Abou-Alfa, MD is a gastrointestinal oncologist, specializing in primary liver cancer, pancreas, gallbladder, and bile duct tumors. His research focuses on improving the effectiveness of cancer therapy by incorporating small novel biological molecules that target cancer into the treatment of chemotherapy-resistant gastrointestinal malignancies, particularly hepatobiliary and pancreatic cancers. He has been active in many clinical trials targeting fibrolamellar (see publications) and is a Scientific Advisor to FCF.

Below is an interview with Dr. Abou-Alfa by the Rare Disease Report in which he discussed what people can expect in the fibrolamellar space over the next several years.

Leave a Comment